Fig. 5: Antibody-mediated targeting of the SLAMF6 dimerization site inhibits the SLAMF6–SLAMF6 interaction.
a, Binding of the SLAMF6 antibody TNC-1 to SLAMF6-ECD in ELISA. Bars indicate the mean values of two technical replicates. b, TNC-1 binding to wild-type and SLAMF6-knockout cells, generated by CRISPR–Cas9 in the AML cell line KG-1 with endogenous expression of SLAMF6. c, Mapping of the TNC-1 binding epitope in SLAMF6 by HDX-MS. The dashed red line denotes the determined epitope. The color scale denotes the change in epitope accessibility by incubation with antibody Fab fragment. d, Three-dimensional model of the SLAMF6 protein based on AlphaFold, with the SLAMF6–SLAMF6 dimerization interface marked in red and the TNC-1 binding site marked in blue. e, Binding of TNC-1 to SLAMF6 on primary T cells with and without preincubation of the cells with SLAMF6-ECD. Data are shown as the mean ± s.e.m. of three T cell donors, normalized to the MFI without preincubation for each donor (two-sided t-test with Welch’s correction, P = 0.010).